An investigation was announced for investors in NASDAQ:SGYP shares concerning possible breaches of fiduciary duties by certain officers and directors at Synergy Pharmaceuticals.
Investors who purchased shares of Synergy Pharmaceuticals Inc (NASDAQ:SGYP) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.
The investigation by a law firm concerns whether certain Synergy Pharmaceuticals Inc officers and directors breached their fiduciary duties and caused damage to the company and its shareholders.
New York based Synergy Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. Synergy Pharmaceuticals Inc reported that its Net Loss increased from $117.50 million in 2015 to $198.61 million in 2016.
Shares of Synergy Pharmaceuticals Inc (NASDAQ:SGYP) declined from $6.73 per share in January 2017 to as low as $3.98 per share on April 6, 2017.
On April 19, 2017, NASDAQ:SGYP shares closed at $4.10 per share.
Those who purchased NASDAQ:SGYP shares have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North – Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com